{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106529","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.414731+00:00","generated_at":"2026-05-17T15:26:59.509002+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xenon Q2 net loss $84.7M; azetukalner Phase 3 X-TOLE2 enrollment complete, topline early 2026","bullets":["Net loss $84.7M vs $57.9M Q2 2024; R&D expenses rose to $75.0M from $49.7M on azetukalner trials.","Phase 3 X-TOLE2 (focal seizures) patient recruitment complete; topline data expected early 2026.","Phase 1 studies underway for XEN1120 (Kv7) and XEN1701 (Nav1.7) pain candidates.","Darren Cline appointed Chief Commercial Officer to lead commercial build for azetukalner launch.","Cash $624.8M as of June 30, 2025; funding expected into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106529","json":"https://secwatch.observer/filing/0000950170-25-106529.json","markdown":"https://secwatch.observer/filing/0000950170-25-106529.md","text":"https://secwatch.observer/filing/0000950170-25-106529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025106529/0000950170-25-106529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025106529/xene-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:26:59.509002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}